Skip to content

Bile Salt Sulfotransferase

Bile salt sulfotransferase is an enzyme involved in the metabolism and detoxification of bile acids and various other steroid compounds within the human body. It belongs to the sulfotransferase enzyme family, a group of enzymes critical for modifying a wide array of endogenous and exogenous substances to facilitate their elimination.

The primary function of bile salt sulfotransferase is to catalyze the transfer of a sulfonate group from a donor molecule, typically 3’-phosphoadenosine 5’-phosphosulfate (PAPS), to an acceptor molecule, such as a bile salt. This process, known as sulfation, significantly increases the hydrophilicity (water solubility) of bile salts. Enhanced water solubility is crucial for efficient excretion of bile salts from the body, primarily through urine and feces, thereby preventing the accumulation of potentially toxic hydrophobic bile acids.

Variations in the activity or expression levels of bile salt sulfotransferase can have implications for an individual’s bile acid homeostasis. Dysregulation of bile acid metabolism is linked to a range of health conditions, including disorders related to fat digestion and absorption, cholesterol metabolism, and various liver diseases where the buildup of bile acids can lead to cellular damage and toxicity. Understanding the role of this enzyme is therefore important for investigating the underlying mechanisms of such metabolic and hepatobiliary disorders.

The study of bile salt sulfotransferase contributes to a broader understanding of fundamental human metabolic processes, detoxification pathways, and the delicate balance of bile acid physiology. Insights gained from this research can inform the development of targeted therapeutic strategies for metabolic disorders, enhance our comprehension of drug metabolism, and provide valuable information regarding genetic factors that influence an individual’s capacity to process and eliminate specific compounds, ultimately impacting overall health outcomes and disease susceptibility.

Methodological and Statistical Constraints

Section titled “Methodological and Statistical Constraints”

Genetic association studies face inherent methodological and statistical challenges that influence the interpretation and generalizability of their findings. Moderate sample sizes, common in early genome-wide association studies (GWAS), can lead to insufficient statistical power, increasing the likelihood of false negative findings and failing to detect modest yet biologically significant associations [1] Conversely, the extensive number of statistical tests performed in GWAS raises the risk of false positive findings and inflated effect sizes if not rigorously adjusted for multiple comparisons [1] The presented statistical significances and estimated effect sizes must therefore be interpreted cautiously, considering the complexity of these analyses [2]

Furthermore, the coverage of single nucleotide polymorphisms (SNPs) in earlier genotyping arrays, such as 100K platforms, may be insufficient to fully capture genetic variation within specific gene regions, potentially missing genuine associations or limiting comprehensive candidate gene analysis[3] Methodological choices, such as performing only sex-pooled analyses, could also obscure sex-specific genetic effects on phenotypes [4] Replication studies are critical, yet historical data indicate that only a fraction of initial associations are consistently replicated, highlighting the need for validation across independent cohorts [1]

Generalizability and Phenotypic Assessment

Section titled “Generalizability and Phenotypic Assessment”

The generalizability of findings from specific cohorts, such as volunteer participants or twin samples, may be limited and not fully applicable to the broader general population [2] This restricts the direct applicability of results to other ethnic groups and may overlook population-specific genetic architectures.

Phenotypic measurements also present challenges, as biomarker levels can be influenced by various factors. For instance, serum markers for iron status are known to fluctuate with the time of day blood is collected and menopausal status . Similarly, rs7254647 , located in proximity to SULT2A1 and BSPH1, could potentially impact SULT2A1 gene regulation or be in linkage disequilibrium with other functional variants that influence sulfotransferase function. Another gene with profound metabolic implications is PNPLA3 (Patatin-like phospholipase domain containing 3), which is deeply involved in the metabolism of triglycerides and lipid droplets within liver cells. Variants such as rs3747207 and rs738409 in PNPLA3are strongly associated with increased liver fat content and the progression of liver diseases, which can indirectly but significantly affect bile acid synthesis and overall liver metabolic capacity, including bile salt sulfotransferase activity.[1] These genetic variations underscore the intricate connections between lipid metabolism, liver health, and the body’s ability to process and detoxify bile acids.

Other variants contribute to broader metabolic and inflammatory processes that can indirectly affect bile salt sulfotransferase activity. For instance,KLKB1 (Kallikrein B1, plasma) encodes plasma kallikrein, an enzyme integral to the kinin-kallikrein system involved in inflammation, blood pressure regulation, and coagulation. The variant rs4241819 in KLKB1 might subtly alter the enzyme’s activity or expression, potentially influencing systemic inflammatory responses that, in turn, can affect liver function and bile acid metabolism. [1] TRIB1AL (Tribbles pseudokinase 1) is related to lipid metabolism, with its functional ortholog TRIB1 playing a role in regulating cholesterol levels by influencing the expression of LDLR and PCSK9. Genetic variation at rs2954031 near TRIB1ALcould therefore contribute to variations in lipid profiles, which are closely linked to overall liver metabolic health and the efficiency of bile salt sulfotransferase. Furthermore,IRF1 (Interferon regulatory factor 1) is a transcription factor critical for immune responses and inflammation. [1] The variant rs6894249 in IRF1 or the adjacent CARINH region might influence immune signaling, potentially affecting liver inflammation and, consequently, the regulation of bile acid synthesis and sulfation pathways.

Several other genetic variations are found in regions with less direct, yet potentially significant, implications for metabolic health. The variant rs2862792 , located within the ZNF680 - BNIP3P44 region, might influence the function of ZNF680, a zinc finger protein involved in transcriptional regulation, whose specific role in liver metabolism or bile acid processing is an ongoing area of research. [1] The variant rs6509332 in BICRA(Bicoid related homeobox transcription factor A) could impact broader developmental or regulatory pathways that indirectly affect liver function and metabolic capacity, including the activity of bile salt sulfotransferase. WhileCRX (Cone-rod homeobox) is primarily known as a transcription factor essential for photoreceptor development in the retina, rs770622350 or other variants in this gene might be linked to systemic traits through pleiotropic effects or linkage disequilibrium with other functionally relevant loci. Similarly, rs1573567 in the VSTM5 - HPRT1P3 region involves VSTM5, a transmembrane protein whose precise functions in bile acid metabolism or liver physiology require further elucidation, but could represent a regulatory hotspot. [1] These variants, though their direct mechanisms are complex, highlight the extensive genetic landscape influencing various physiological processes that collectively contribute to metabolic health.

The provided research studies do not contain specific information regarding the pharmacogenetics of bile salt sulfotransferase. Therefore, a section on this topic cannot be generated based on the given context.

RS IDGeneRelated Traits
rs212099 SULT2A1bile salt sulfotransferase measurement
rs4241819 KLKB1apolipoprotein A-IV measurement
thrombin generation potential measurement, thrombomodulin measurement
protachykinin-1 measurement
interleukin-2 measurement
acidic leucine-rich nuclear phosphoprotein 32 family member b measurement
rs7254647 SULT2A1 - BSPH1bile salt sulfotransferase measurement
rs3747207
rs738409
PNPLA3platelet count
serum alanine aminotransferase amount
aspartate aminotransferase measurement
triglyceride measurement
non-alcoholic fatty liver disease
rs2862792 ZNF680 - BNIP3P445alpha-pregnan-diol disulfate measurement
bile salt sulfotransferase measurement
body height
rs6509332 BICRAbile salt sulfotransferase measurement
rs1573567 VSTM5 - HPRT1P3bile salt sulfotransferase measurement
rs770622350 CRXbile salt sulfotransferase measurement
rs2954031 TRIB1ALtriglyceride measurement
neutrophil count, eosinophil count
granulocyte count
neutrophil count, basophil count
myeloid leukocyte count
rs6894249 IRF1, CARINHasthma
systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, rheumatoid factor negative, oligoarticular juvenile idiopathic arthritis
low density lipoprotein cholesterol measurement
tryptophan betaine measurement
total cholesterol measurement

[1] Benjamin, Emelia J., et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Med Genet 8 (2007): S11.

[2] Benyamin, Beben, et al. “Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels.”Am J Hum Genet 83 (2008): 727-36.

[3] O’Donnell, Christopher J., et al. “Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI’s Framingham Heart Study.”BMC Med Genet 8 (2007): S12.

[4] Yang, Qiong, et al. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.”BMC Med Genet 8 (2007): S10.